|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
2/16/2010 9:47:56 AM
SHREVEPORT, La.--(BUSINESS WIRE)--Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for drug dependence, smoking cessation and obesity, announced today that the company has retained Exponential Pharma Ventures LLC to assist in establishing a clinical development partnership for its cocaine dependence program with a fully integrated pharmaceutical company. Exponential Pharma Ventures, a company specialized in development of early stage biomedical technology through pharmaceutical partnerships, is seeking a partner to advance Embera’s lead product, EMB-001C into phase 2a clinical trials. The pharmaceutical partner will receive an option to license and commercialize the product after clinical proof of concept. Embera and Exponential have already initiated discussions with prospective partners. EMB-001C is a combination drug product that has recently demonstrated preliminary clinical proof of concept in a randomized, double-blind, placebo–controlled pilot study in cocaine-dependent human subjects.
|
|
|
|
|
|
|
|
|
|
|